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 ABSTRACT 
Atherosclerosis, an arterial ailment, is a major cause of cardiovascular diseases (CVD), 
which cause more than 17 million deaths each year and the number is expected to rise. In 
recent years atherosclerosis has been shown to be an inflammatory condition involving 
activated immunocompetent cells, including T-cells, macrophages and dendritic cells 
(DC), but the mechanism by which these cells are activated remains to be elucidated in 
detail. Treatment of atherosclerosis is still not satisfactory, primarily due to the complex 
underlying mechanisms, especially with respect to inflammation and immunity. An 
additional characteristic of atherosclerosis is the accumulation of dead cells in a necrotic 
core in the plaques, as well as of oxidized forms of low density lipoprotein (Ox-LDL). 
Interestingly, the prevalence of atherosclerotic plaques and CVD are elevated among 
individuals with systemic inflammatory diseases, such as systemic lupus erythematosus 
(SLE). 
These studies focused on the responses of major immunocompetent cells, such as T-cells, 
DC and macrophages to potential antigens, including heat shock protein (HSP) 60 and 90, 
phosphorylcholine (PC) and malondialdehyde (MDA), of which the latter two are 
components of Ox-LDL. Such investigations are related to potential links between the 
prototypical autoimmune disease SLE and CVD, as well as the development of novel 
therapies against atherosclerosis.   
For these purposes, we examined peripheral blood cells from healthy donors and patients 
with SLE, as well as cells obtained from human atherosclerotic plaques in connection with 
operations for CVD. We also studied a well-characterized cohort of SLE-patients, 
SLEVIC. 
Overall, we found that antibodies against phosphorylcholine (PC) and MDA were 
correlated with a lower prevalence of atherosclerosis among patients with SLE. Potential 
mechanisms involve enhanced uptake of apoptotic cells and a reduction in oxidative stress. 
Furthermore, anti-PC antibodies promoted polarization of T-reg cells, which may protect 
against both SLE and atherosclerosis. Surprisingly, production of these antibodies was 
dependent on T-cells.  
HSP60 and HSP90 exerted pro-inflammatory effects on DCs and DCs stimulated in this 
manner induced pro-inflammatory activation of T-cells obtained from human peripheral 
blood and atherosclerotic plaques. Expression of HSP60 was induced by OxLDL.  
A conjugate of MDA with human serum albumin (MDA-HSA) promoted pro-
inflammatory activation of DCs and, subsequently, of T-cells obtained from human 
peripheral blood and atherosclerotic plaques via these DCs. Importantly, MDA-HSA also 
activated such T-cells directly. Both MDA-HSA itself and T-cells exposed to MDA-HSA 
promoted polarization of pro-inflammatory M1 macrophages. Annexin A5 inhibited the 
 pro-inflammatory effects of HSP60 (in line with our previous identification of this 
substance as potentially protective against atherosclerosis) and anti-MDA antibodies or an 
inhibitor of mitochondrial production of reactive oxygen species (ROS) attenuated the 
activation of T-cells by MDA-HSA.  
Taken together, immunity plays an important role in connection with atherosclerosis and 
atherosclerotic plaques. Potential links between autoimmunity and atherosclerosis were 
identified. In particular, HSP60 and MDA may be important activators of immune cells in 
connection with atherosclerosis and, importantly, antibodies against PC and MDA, 
Annexin A5 and inhibitors of ROS could prove to be of value for prevention of and/or 
therapy against atherosclerosis.  
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1. Introduction 
Atherosclerosis, start with the formation of lesions in the arterial wall, similar to those 
present in mummies more than 1000 years old1. Already in the 19th century, Rudlof 
Virchow and Carl von Rokitansky described cellular inflammatory changes, such as 
leukocyte diapedesis in the atherosclerosis vessel wall, although Rokitansky thought these 
changes were secondary, whereas Virchow proposed that this inflammation was a primary 
cause of disease2 . In 1910 Windaus demonstrated the presence of calcified and connective 
tissue in atherosclerotic plaque and three years later Anitschkow and Chaltow reported that 
a cholesterol-rich diet is a risk factor for atherosclerosis2. The role played by inflammation 
in atherosclerosis, is now extensively documented2-4.  
Inflammatory diseases are primarily characterized by immunological changes4. 
Inflammation is a body’s defensive system but now it is well known that chronic 
inflammation can cause disease or associated with disease, e.g., cardiovascular disease 
(CVD) 5, 6. The prevalence of chronic inflammatory diseases has risen during the past few 
decades but reason not yet clearly understood. Association between inflammation and 
diseases can be explainable only when the causes of the disease are the dysregulation of 
inflammatory response4. As revealed by epidemiological and clinical studies,  
atherosclerosis is in the turn the major cause of CVD, although the exact relationship or 
precise chain of events remain to be elucidated7, 8. Atherosclerosis is the major cause of 
CVD 6, 9, where inflammation plays a role in atherogenesis10. The ischemic heart diseases, 
stroke and hypertension very often caused by atherosclerosis11,  were not a serious burden 
until the beginning of the 20th century, but it has been long now that these became a major 
health problem in Western countries, such as Europe or US12.  These inflammatory diseases 
are the leading cause of mortality in the Western world12, 13. In Europe, cardiovascular 
mortality is twice that from cancers14, and CVD are also becoming a problem in developing 
countries12, 15. It has been estimated that each year 17.3 million die from both ischemic 
heart disease and stroke. Recent data shows death from CVD in the year 2013 was 31.5% 
of total deaths, and expected to incresae16,17.  
The many risk factors for atherosclerosis or CVD are classified as classic or traditional18, 
non-traditional or novel19, modifiable 20 and non-modifiable21. Atherosclerotic CVD 
include age, sex, cigarettes smoking, diabetes 22melitus, hypertension, dyslipidemia, 
obesity and inherited risk factors 22, 23.  Although  used for generalized evaluation, it may 
be inappropriate to apply this factors in the  assessment of any individual patient 23. Non-
traditional risk factors, some still controversial include genetic variation, malnutrition, 
vascular calcification, thrombosis markers, platelet-related factors, lipid-related factors, 
inflammation, homocysteine, circulating DNA and oxidative stress, and have not been 
examined as extensively as traditional risk factors 23, 24. Certain other diseases, including 
systemic lupus erythematosus, chronic kidney diseases, arthritis, vasculitides, human 
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immunodeficiency virus and malignancy, as well as heavy alcohol consumption have also 
been proposed to enhance the risk for premature atherosclerosis 23.  Lifestyle can be 
considered as modifiable risk factors whereas sex, age and family history are considered 
as non-modifiable risk factors20, 21.  Most of these risk factors are related in one way or 
another to inflammation and thus body`s immune system can play diverse functions.  
1.1 The immune system  
Immunity is the body’s defensive system against infections, diseases or unwanted 
particles25. Immunity is a system or network of cells, tissues or organs. In general, foreign 
particles or microorganisms induce the immune response. The particles or molecules 
capable of inducing an immune response are called antigen. The antigen can be a protein, 
lipid, phospholipid or polysaccharide. Certain small molecules called hapten, which cannot 
themselve induce immunity but in conjugation with a carrier (protein, carbohydrate, lipid), 
act as antigen26. The two types of immune responses  are referred to as innate and 
adaptive27, 28. Innate immunity, the body`s first line of defense, is non-specific and short 
term; whereas the adaptive immune system is specific. A variety of cells participate 
together and secrete products such as cytokines, chemokines or antibodies.  
The immune cells (white blood cells) include B, T, dendritic cells (DCs), macrophages and 
neutrophils. The T-cells that are produced and mature in the thymus, where they are taught 
to detect non-self-antigen, are mainly of two types, i.e., helper T-cells, and cytotoxic T-
cells. Cytotoxic T-cells, also called killer T-cells, can kill the infected cells or cells that 
express certain antigens. Helper T-cells help B-cells to produce antibodies against the 
antigen and also, help cytotoxic T-cells to kill the affected cells and activate macrophages 
and DCs. These subset of T-cells are characterized by unique markers CD8+ (cytotoxic T 
cell) or CD4+ (helper T cell).  
CD4+ T-cells are divided further into different subtypes, including Th1, Th2, Th17, and T-
regulatory(T-reg) cells. Th1 and Th17 cells are pro-inflammatory whereas Th2 are anti-
inflammatory. T-regs suppress pro-inflammatory responses. DCs are the best-known 
antigen presenting cells, main function is to present antigen to T-cells and thereby activate 
the immune system, so that their maturation is a key aspect of immune regulation. 
Macrophages phagocytize infectious agents, dead cells and the body’s unwanted debris and 
also act as antigen-presenting cells. 
Adaptive immunity is mediated either by cells or antibodies (so called humoral immunity). 
B-cells producing antibodies, while also acting as antigen-presenting cells. They interact 
with T-cells through antigen and produce antibodies, which is T-cell dependent, but also 
can produce antibodies without the help of T-cells, so called T- independent antibodies, 
referred to as T15 antibodies. T-independent antibodies are mainly natural antibodies. Both 
innate and adaptive immunity can under certain circumstances, lead to inflammation and 
autoimmunity. After the anatomical barrier, inflammation is the first response of the 
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immune system. Short-term inflammation is called acute and a long-lasting inflammation 
is called chronic inflammation 5. 
1.2 Inflammation: cause, and consequences   
At the tissue level, inflammation mainly develops through steps of redness, swelling heat, 
and pain in response to microbial or non-microbial stimuli (Table-1). Certain non-
microbial endogenous inducers such as tissue injury or damage link to microbial inducers. 
Depending on the location and type of stimulus, the inflammatory response can vary but 
certain steps are always involved:  1) recognition of the stimulus by pattern recognition 
receptors (PRRs); 2) activation of inflammatory pathway; 3) release of inflammatory 
markers; and 4) recruitment of inflammatory cells to the site of injury29.  
Acute inflammation results in healing or repair of tissue damage whereas in attempt to 
repair, chronic inflammation may lead to the tissues destruction and thus disease. In 
addition to infection, tissue injury or destruction causes inflammation, but depending on 
circumstances effect can vary30. The two main phases of acute inflammation are referred 
to as initiation and resolution31. Immune cells recruited to the site of injury by cellular 
products such as prostaglandin and leukotrienes, begin their activities there, primarily 
clearance and repair of damaged tissue. Acute inflammation can sometimes develop into 
chronic inflammation, and both can continuously reinitiate and thus co-exist, but the main 
question is the frequency and fate of inflammation.  
It remains unclear exactly when inflammation resolves and when it fails32. A globally 
enormous number of diseases including atherosclerosis, involve chronic or non-resolving 
inflammation32. For the inflammation initiation or regulation, 4 different factors are 
involved, defined as inducer, sensor, mediator, and effector. Some exogenous and 
endogenous inducers are presented in the table -1. Toxic substances, chemical, allergens 
or different types of foreign bodies are belonging to non-microbial exogenous 
inflammatory inducers30. The pathogen-associated molecular pattern are recognized 
mostly by pattern recognition receptors (PRRs) and triggers inflammatory signals. Danger-
associated molecular pattern (DAMPs) mainly non-microbial molecules but can be 
recognized also by PRRs. The different types of PRRs include toll-like receptors (TLRs), 
retinoic-inducible gene I-like receptors, C-type lectin receptors and NOD-like receptors. 
Myeloid differentiation factor-88 mediates the transmission of PAMPs and DAMPs from 
TLRs, activating nuclear intracellular signaling pathways, involve NF-kB and MAP 
kinase, and janus kinase-signal transducer and activation of transcription. Nuclear 
translocation of specific transcriptions factors triggers the inflammatory pathway29.  
Some non-microbial inducers of inflammation can also be detected by TLRs but in most 
cases their detectors are still unknown. Like exogenous inducers, endogenous inducers can 
play a major role in both acute or chronic inflammation. Inducers of chronic inflammation 
include crystals of monosodium urate, calcium pyrophosphate dihydrosate, and Ox-LDL, 
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or by-products of Ox-LDL and epitopes of these5, 33-35. The inducers trigger or produce 
various mediators include components of complement, lipid mediators, cytokines, 
chemokines, and proteolytic enzymes. In addition, irregular production of reactive oxygen 
species (ROS) in response to inducers or mediators can initiate an endogenous 
inflammatory response.  
 
Table-1. Microbial and non-microbial inducers of inflammation.  
 
1.3 ROS and inflammation 
By products of aerobic metabolisms 49, including (O2
-) superoxide, (OH-) hydroxyl radical 
and (H2O2) hydrogen peroxide are classified as ROS and react with biological molecules 
to produce results that are usually  deleterious. ROS production is associated with oxidative 
stress and may damage DNA, lipids or proteins, induce cellular dysfunction and thus 
contribute to inflammmation48.  Indeed, metabolic and inflammatory diseases, including 
atherosclerosis, are associated with excessive   ROS production or imbalance in redox 
pathways. At the same time normal biological processes are also regulated by ROS50.  
Inducers often stimulate inflammatory signaling via ROS. NF-kB signaling plays a vital 
role in inflammation and has also been reported to be involved in insulin resistance 
associated with obesity and atherosclerosis. In response to inflammatory inducers, ROS 
activates NF-kB signaling is a manner dependent on the location and/or amount and nature 
of the ROS. 
ROS are generated in mitochondria, cytoplasm, and peroxisome. Mitochondrial H2O2 is 
involved in NF-kB activation of endothelial cells in rat arteries51and, furthermore, 
activation of NF-kB by hypoxia was abolished by inhibiting mitochondrial ROS 52. It is 
assumed that secondary products of ROS can also play a role in inflammatory signaling. 
Lipid peroxidation generates various products e.g., oxidized phospholipid, which can 
activate NF-kB or other inflammatory signaling and also regenerate ROS.  
Microbial inducers                 Non-microbial inducers  
Bacterial lipopolysachraide36 
Microbial peptides37 
Glycolipid37 
Bacterial short-chain fatty acids38 
Bacterial Lipoteichoic acid39 
DNA39   
Fungi, virus40 
Exogenous  Endogenous  
Smoking41 
Air particles42 
Nano particles43   
Nitrogen oxide44 
Ox-LDL45 
Fatty acids46  
Self-DNA47  
ROS48  
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It is still not clear whether secondary ROS is protective or provoke the inflammatory 
response, this probably depends on the amount of ROS and cell and/or nature of the 
stressor. However, in the case of atherosclerosis, ROS or oxidative stress have been linked 
to certain endogenous inflammatory inducers53.  Endogenous inducers play a major role in 
atherosclerosis. In atherosclerosis, Ox-LDL derived lipid by-products considered as the 
main signaling initiator or inflammatory inducer45.  
1.4 Inflammatory inducers or oxidation-specific epitopes in Atherosclerosis  
Native LDL deposited in the artery can be modified/oxidized to yield a set of complex 
products 54, 55,including free and esterified fatty acids, aldehydes such as malondialdehyde, 
oxidized phospholipids, and protein carbonyls, among many others depending on the type 
and duration of oxidation54.  It has been proposed that Ox-LDL contains 600 molecules of 
free cholesterol, 700 phospholipids, 1600 cholesteryl esters, 185 triglycerides and one 
molecule of Apo lipoprotein B10055. Specific oxidized epitopes of LDL constitute a 
danger-associated molecular pattern (DAMP)56, and are recognized by pattern recognition 
receptors57. It is possible that not all Ox-LDL expose the same epitopes, which can result 
in varying consequences.  
Phospholipids are among the epitopes or products of Ox-LD most studied in the context of 
inflmmation58. Phosphatidylcholine (PTC) is an important component in LDL59, also it can 
be found in an outer layer of the cell membrane. In the chemical structure of PTC, the 
unsaturated fatty acid is also present in addition to a saturated fatty acid with glycerol. 
Glycerol also links to phosphorylcholine (PC) comprised of a phosphate group and a 
choline group. Another phospholipid, lysophosphatidylcholine (LPC) is a derivative of 
PTC. The LPC produced from PTC by removing an unsaturated fatty acid.  
The unsaturated fatty acid region in PTC prone to oxidation and impaired  biosynthesis of 
PTC is linked to atherosclerosis59, 60, where impaired biosynthesis or lack of 
phosphatidylcholine attenuates atherosclerosis. On the other hand, one common head 
group of PTC, phosphorylcholine (PC), is anti-inflammatory according to several studies28, 
61,a curious finding in light of the fact that PTC is pro-inflammatory. Perhaps when PC is 
linked to platelet activating factor, protein, carbohydrate or some other molecule it acts in 
a different manner62, 63. Another possibility is that the fatty acids moieties in PTC are 
involved in inflammatory properties64, 65.  
Malondialdehyde (MDA), a product of lipid peroxidation that induces oxidative stress, is 
involved in the development of various diseases including atherosclerosis55, 66, 67.MDA can 
covalently modify proteins or lipids and thus generate more complex products. MDA 
acetaldehyde and MDA-modified LDL are produced by MDA. The MDA epitope of Ox-
LDL modified in this manner can differ with respect to immunogenicity or reactivity to 
antibody68-71. Understanding MDA-induced inflammation can be useful in connection with 
therapeutic approaches to atherosclerosis, but the underlying mechanism(s) remains to be 
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identified66. In addition to Ox-LDL or their related products, some other molecules have 
been shown to be important inflammatory regulators in atherosclerosis. In this regard, heat 
shock proteins are under investigation.  
1.5 Heat shock proteins in connection with atherosclerosis  
Heat shock proteins (HSP), also known as stress proteins, are expressed in response to heat 
or toxic substances. On the basis of their molecular weight, the HSP is classified into 
HSP10, HSP40, HSP60, HSP70, HSP90 and so on72 and several studies suggest that they 
play a role in cardiovascular diseases73-76. All organisms express HSP60, and the 
prokaryotic and eukaryotic (including human) forms, display > 90% sequence homology 
and overall homology in protein and DNA level is more than 50 percent, even in some 
cases it is 70 percent. Microbial materials acquired by infections or vaccination induce 
immunity in humans against bacterial HSP60. Because of sequence homology, it can cause 
cross-reactivity with endothelial cells-produced autologous HSP6077. Involvement of 
HSP60 in atherosclerosis was originally proposed by G. Wick and co-workers in 1990s on 
the basis of their findings of induction of atherosclerosis in animal models, induced by 
HSP65 immunization78. Since then this proposal has been examined in other animal models 
as well as in humans. Antibodies against HSP60 may be pathogenic and thus associated 
with CVD and/or atherosclerosis79, 80. Although the detailed adaptive response to this 
protein is not known and even less is known about the innate immune response. Our 
previous research has shown that in connection with an inflammatory Ox-LDL-induced 
response, heat shock proteins acts as co-stimulatory factors. T-cells activation by Ox-LDL 
was inhibited by silencing HSP60 and HSP90, suggesting their involvement in 
atherosclerosis progression and/or development81. 
 
1.6 Iinitiation, progression and development of atherosclerosis  
Atherosclerotic lesions (plaques) contain activated cells, in particular immune cells, which 
including macrophages, dendritic cells and T-cells as well as an abundance of dead cells. 
Although lipid deposition in the artery might initiate atherosclerosis, the initiation and 
progression of atherosclerosis remains poorly understood. It is widely thought that 
inflammation caused by Ox-LDL is an important initiator of atherosclerotic plaque 
formation82 that may develop in response to inflammation83. However, even though 
inflammatory components in plaque development and rupture has been implicated84 and 
inflammatory mediators of adaptive and innate immunity e.g.,  various receptors, 
cytokines, and chemokines appear to be involved in plaque formation and rupture, the 
detail mechanisms need to be elucidated 85. The artery is the blood vessel, carries out blood, 
nutrients and some other molecules including cholesterol. Lipoproteins that carry out 
cholesterol are mainly 2 types the low-density lipoprotein (LDL) and high-density 
lipoprotein(HDL)86.  In the LDL, the protein content is low, whereas HDL has high protein 
content. HDL considered being “good cholesterol”, whereas LDL is “bad cholesterol”. In 
7 
 
HDL, ApoA-1 is the major component, functioning as an anti-inflammatory factor in 
atherosclerosis.  
It is generally believed that atherosclerosis is initiated by the deposition of the LDL in the 
artery. Tunica externa comprise of connective tissue, tunica media made up of smooth 
muscle cells and tunica intima is made up of endothelial cells. During transportation, some 
of the circulating LDL attached to the artery wall and it is probably the endothelial cells 
facilitate the entry of LDL into the vessel intima, where it is oxidized or modified 
enzymatically.  
Ox-LDL is then aggregate there and phagocytized by macrophages. Irregular uptake of Ox-
LDL leading to the formation of foam cell and thus plaque progression (fig:1). The 
composition of plagues and thereby their stability differ 87. Depending on this composition 
or type, plaque can be more unstable or vulnerable, these plaques are more prone to 
rupture84, 87, 88. The first plaque rupture was reported in 1844.  
 
Fig-1: A healthy and an atherosclerotic artery.  
On the other hand , HDL or Apo-A1 is athero-protective in several ways, mainly by  
inhibiting the early stage of atherosclerosis, suppressing adhesion molecules; inhibiting 
secretion of inflammatory cytokines89 or chemokines90; as well as attenuating LDL 
oxidation91; and influencing monocyte chemotaxis90.  
HDL may also protect later on by promoting cholesterol efflux from foam cell92, but this 
has not been much investigated the role of HDL in late stage of atherosclerosis.  
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 The concern about the HDL recently published93. The predictive effect of HDL effect 
depends mainly on age, with more pronounced protection in young than older mice. 
Moreover, HDL did not reduce atherosclerosis or cardiovascular events in elderly 
patients.93 Further characterization revealed that a deficiency in scavenger receptor-B1, 
HDL receptor, aggravates atherosclerosis, even in the presence of a higher level of HDL,94 
indicating the importance of the receptors on the cell surface. All the recent advances in 
cellular involvement highlight in to the understanding more in cellular biology of different 
immune cell types in atherogenesis.  
1.7 Different types of immune cells and Atherosclerosis 
As already mentioned, atherosclerosis is characterized by activated cell types including 
macrophages, DCs, T-cell and B-cell. These activated cells play inflammatory roles in 
atherosclerosis95. 
1.7.1 Macrophages  
Macrophages clear Ox-LDL, a beneficial activity that can also exert adverse effects96. 
Foam cells derived from macrophages that have taken up Ox-LDL, trigger an inflammatory 
response and can become inert and/or undergo apoptosis and/or necrosis. Macrophages are 
the most abundant cells in plaques, where they play a vital role in connection with 
atherosclerosis. Macrophage-secreted inflammatory molecules activate other cells types, 
and attract monocytes.  
Among other activities, macrophages proliferate in atherosclerotic lesions, but number of 
macrophages that come from the recruitment of circulating monocytes and subsequent 
differentiation into macrophages is still a puzzle97. These monocytes might be polarized 
into M1 macrophages that secrete pro-atherosclerotic cytokines and induce production of 
reactive species of oxygen and nitrogen. Another type, M2 macrophages also present in 
atherosclerotic plaques98. In vitro and animal studies suggest that plaque inflammation is 
caused by M1 and resolved by the M2 macrophages also present in lessions96. There are 
also some resident macrophages in the aorta.  
The macrophage (macro=big, phage =eater) is well known as a phagocytic cell. 
Phagocytosis of apoptotic or dead cells in the context of atherosclerosis is not well 
explained, although such inhibits secretion of pro-inflammatory cytokines. Apoptosis or 
dead cells are one of the major characteristic features of atherosclerosis, and impaired 
phagocytosis has been proposed to make plaques more vulnerable to rupture.  Although, 
the effect of phagocytosis in atherosclerosis is not well understood99, but improved 
understanding of macrophage activation may help in the development of target-specific 
safer drugs100.  
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1.7.2 Dendritic cell 
With their dendron (the Greek word for tree)-like structure, dendritic cells (DCs) are the 
best known for antigen presentation, the initial step  in adaptive immune responses101. 
These cells constitute a bridge between innate and adaptive immunity. DC originates in 
bone marrow from common progenitors and has three stages as defined precursors, 
immature and mature stage. Precursors DCs leave the bone marrow and circulate in the 
bloodstream for a different time and develop into the immature stage in several ways. 
Tissue monocytes can differentiate into DCs and play an important role in immunity102. 
According to the origin and functional disposition, DCs can be sub divided into myeloid 
and plasmatocyte lymphoid DCs, suggested to be involved T-cell activation and T-cell 
tolerance, respectively 103-106. The types of DCs including those derived from monocytes, 
in healthy and atherosclerotic mice differ. DCs are also present in healthy human arterial 
intima107, with elevated numbers in atherosclerotic plaques108. DCs may activate T-cells 
and thus destabilize plaque108. In advanced plaques, most of the DCs are activated and 
cluster with T-cells, which suggest that DCs activation within arterial wall, and plaques 
growth and inflammation are associated with activated DCs in the arterial wall76. On the 
other hand, tolerogenic DCs may be as athero-protective109, improving plaque stability110. 
However, DCs phenotype in the context of clinical importance still unknown. The 
recruitment and proliferation of DCs in atherosclerotic lesions are lots remain to be 
characterized111.  
1.7.3 T-cell 
T-cells are generated in the thymus, and the most abundant cells in atherosclerotic 
plaques112  consisting of 10 % of the total cells 10. Seventy percent of these T-cells are 
CD4+ T-cells  and the remaining CD8+ T-cells113. Most of the CD4+ T-cells in plaques are 
pro-inflammatory Th1 T-cells, although Th2, Th17, T-reg, and NKT cells are also present 
in plaques. A different subset of T-cells has a different role in atherosclerosis, as for 
example Th1 and T-reg have the opposite effect on atherosclerosis. Th1 cells have been 
proposed to accelerate atherosclerosis whereas T-reg reduces inflammation and plaque 
formation.  
In mice, deficiency in CD4+ T-cells provided athero-protection, whereas disease was 
accelerated by transfer of such T-cells114, 115. CD8+ T cells may not play any important role 
in atherosclerosis, since a deficiency in these cells did not affect the size of atherosclerotic 
plaque115. However, in one study transfer of CD8+ T cells in mice was atheorprotctive116. 
Th2 cells were believed to be protective, but this is now controversial. Deletion of IL-5 and 
IL-13, cytokines secreted by Th2 cells, accelerate the atherosclerorsis117, 118 while IL-4 
deficiency reduce severity of atherosclerosis119, 120.  
The newly identified IL-17-producing Th17 cells have been shown to be involved in 
atherogenesis, being present in the aortic sinus of Ldlr−/− (low-density lipoprotein receptor-
deficient mice) and ApoE-/- mice121, IL-17 appears to be protective together with higher 
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levels of IL-10, but are pro atherogenic in the presence of higher levels of INF gamma 
cytokines.  
Th17 cells  produce IL-17,  is pro-atherogenic and depletion of this cytokine is shown to 
be athero-protective 122-125 but other studies showed slow progression of atherosclerosis by 
IL-17126, 127. The complex pathway of plaque rupture is not yet completely understood but 
the role of T-cells has been implicated in this process109.  
1.7.4 B-cell 
The B-cell, is developed in the  bone marrow and finally matured in the spleen128. Because 
of different types of antibodies production, their role in connection with atherosclerosis 
still controversial10. Depletion of B-cells augmented plaque formation whereas transfer of 
these cells attenuated development of atherosclerosis129. In some other studies, an effect of 
B-cells deficiency130 and beneficial role of IgM antibodies produced by B1 cells on vessel 
wall131 or protective role against atherosclerosis were reported132. Among the 5 different 
isotypes of antibodies, IgM can be generated without previous infection or immunization 
and are therefore called natural antibodies 133. Such natural antibodies are believed to be 
T-cell indepednet antibodies, while providing bridging between innate and adaptive 
immunity134. Studies indicate that B1 cells are athero-protective and B2 cells are  pro-
atherogenic135, 136.  
Although the overall role of B-cells in connection with atherosclerosis appears to be 
protective but subpopulation may play different roles. CD19+ CD40+ B cells were 
negatively associated with stroke whereas CD19+ CD86+ B cells showed a positive 
association with stroke137. Furthermore, B-cells switched or unswitched were protective 
against secondary CVD event138.     
However,  anti-PC antibodies believed to be natural antibodies and has been shown to be 
negatively correlated with CVD139. It has been proposed that these antibodies bind to PC 
epitopes in Ox-LDL as well  as to apoptotic cells, and even to microorganisms exposing 
PC epitopes140, 141. In animal study, showed immunization of PC-IgM reduces 
atherosclerosis progression 142. In addition, IgM antibodies against MDA were recently 
shown by our group to be a  marker of protection and potential regulator of CVD143. 
 Levels of certain natural antibodies provide a link between atherosclerosis and 
autoimmune diseases144.  
 1.8 The relationship between autoimmune and cardiovascular diseases  
The concept of autoimmunity was introduced in 1900s. The main pathogenic factor, 
antibody involved  in autoimmune disease was also discovered in the early 1900s but until 
1940 the concept of autoimmunity was an over shadow145.  Waaler in 1940 discovered 
rheumatoid factor, later on, identified IgM type antibodies146. In the past, autoimmune 
disease considered as rare diseases but today 3-5% of world`s population suffers from 
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around 100 types of autoimmune diseases 147. The immune system has a sense for 
distinguishing self and non-self-particles but when this signal misguided, it recognizes 
body’s own cells or particles as antigen. Body’s immunity against own particles leads to 
autoimmune diseases148 and leads organ damage and thus promote different disease (Fig: 
2).  Autoimmune diseases are also one of the major health problems with the significant 
cause of morbidity and mortality149, even more, also major complication is that these 
diseases have a link with CVD.  Multiple rheumatic diseases including systemic lupus 
erythematosus (SLE) have a higher risk of developing CVD or atherosclerosis150, 151.  
SLE is characterized by the formation of pathogenic autoantibodies, including antibodies 
against DNA, also antibodies against cardiolipin considered as a disease marker, which can 
contribute to diseases complications or pathogenesis152. SLE also called butterfly rash due 
to visible butterfly shape inflamed area in the face. Increased risk of CVD in SLE was 
shown by Urowitz et al. for the first time in 1976153. The risk of CVD in SLE is already 
well known, which is mostly shown by epidemiological association studies. The incidence 
of atherosclerosis in women with SLE in comparing women with no SLE is 5-9 times 
higher154. Moreover, the risk of myocardial infarction is 50 times higher in the individuals 
with SLE in comparison to the individuals without SLE155 but the mechanism has not been 
elucidated. Increased atherosclerosis showed also in autoimmunity animal model156, 157. 
TNF ligand or TNF receptor superfamily ligand was shown to be linked with defective in 
clearance of apoptotic cells and atherosclerosis156, as well as to the inflammation in arterial 
wall associated with increased atherosclerosis157. In this same study, plaque progression 
was associated with activation of T, B, and endothelial cell and also monocyte recruitment 
and accumulation of apoptotic debris.  
The mechanism(s) by which, autoimunity elevates the risk of CVD has not yet been 
established.  In vitro, ex vivo158 or animal studies159 could be more important for 
mechanistic studies of the link between autoimmunity and CVD. The link between these 2 
diseases are firmly established but more research is necessary to understand the mechanism 
of cause154. Although the animal model of lupus displays enhanced atherosclerosis160 the 
animal model of SLE develops only a few features relevant to human disease154.  
1.9. An animal model of atherosclerosis  
The animal model is becoming an useful tool for the study of atherosclerosis161, 162. Several 
animal models have been developed in atherosclerosis studies, for an understanding of 
disease initiation and progression. In 1908, Ignatowski in a rabbit model reported 
atherogenesis161. Since then subsequent studies of atherosclerosis on the animal models are 
ongoing and also genetically modified animals are available for specific studies. Mice, rats, 
non-human primate, pigs, birds and some other animal models are used for atherosclerosis 
studies. 
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Figure: The General relationship between autoimmune and other disease. The immune system produces 
antibodies against the body`s own components and these form immune complex that with trigger auto-
immune diseases. Eventually, chronic inflammation damages to different organs and induces other diseases.  
 
Most of the information on the underlying pathophysiological mechanism of diseases is 
provided by rodents, swine, and rabbits.  Animal models are extensively used for 
cardiovascular or atherosclerosis studies but consideration of a proper animal model is 
important. One of the important features of an ideal or proper animal model is resemblance 
to human conditions. Despite extensive studies on animal models, each animal model for 
atherosclerosis has limitations. At present, mice are mostly used than another animal for 
atherosclerosis studies. Some of the advantages and limitations of mice models used in 
atherosclerosis research are listed in Table-2. The limitations or gap between in vitro and 
animal studies can be bridged by ex vivo studies163 for atherosclerosis and thus 
cardiovascular research.  
Table-2. Advantages and limitations of the animal models of atherosclerosis.  
        Advantages                                          Limitation/Disadvantages 
 Genetic manipulation  
 Induction of atherosclerosis in wild-type 
mice requires a toxic diet 
 Low cost    Circulating cholesterol  HDL, not LDL 
 Comparatively little time 
required for study  
 Cardiovascular anatomy and physiology 
are differ from   those of humans 
 Availability   Genetically modified mice needed  
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1.10 Cardiovascular research: A story of a multiple sides  
Already mentioned that death rate in cardiovascular diseases is still higher but 
comparatively the rate declined significantly, even though prevalence has increased 164. In 
addition to the development of several areas in CVD, scientific research plays important 
role in preventing the death rate of CVD, although identification and development of 
proper therapy or medication are still challenging. The research from bench to bench side 
has lunched therapeutic to prevent atherosclerotic disorder or heart failure. Translational 
research is explained in many ways but it is generally accepted that the final target of 
translational research is the patient and to improve care164. The traditional explanation of 
translational research simply identifying a new mechanism and discovery of potential 
therapeutic in a basic or experimental research setting, the approach validation in a clinical 
setting and introduce it in clinical practice. It is true that there are many success stories of 
CVD research but at the time unexpected difference has been observed from different 
research. As for example between genomic studies and animal models show the 
discrepancy. Hence introduction a new therapeutic becoming more unrealistic. In recent 
decades’ developments in biological and genetic research have unraveled some of the 
pathological features of atherosclerosis, but there still is a gap between basic research and 
clinical practice that must be bridged165.   
The methodology employed in CVD research has not improved significantly in recent 
years. For example, miRNA research is attracting attention, but methodologies are not 
optimized. RT-PCR, droplet-based PCR and loop-based digital PCR microarray, RNA seq 
are used to quantify miRNA. However to reduce variability, normalization to a common 
set of miRNAs as well as an internal control and appropriate statistical analysis, are 
necessary166. The most valuable question is what is the next best in the research of 
cardiovascular diseases167. Different focuses on cardiovascular research topics include, 
cardiac fibrosis, metabolic dysfunction, signaling associated with heart failure, oxidative 
stress and RNA biology, as well as most importantly include novel therapies. Many such 
approaches appear promising, but the main limitation is irreproducibility and improper 
study design is also a major concern in the connection with cardiovascular research, still 
none of approaches could not reach on the stage to pay attention for refocusing.  In clinical 
trial, those who experience adverse side-effects are often excluded and discontinue the 
medication168. In this case, a clinical trial could be misinterpreting. One article published 
recently, screened 28636 publications but finally according to their inclusion criteria, 
included only 3396 in their analysis169. One-third of the studies, has focused on 
therapeutics, mice or rat were mostly used, accounted to be 89.8% cases. One of the main 
issues in cardiovascular research is lack of reproducibility, in addition, discussed earlier 
that animal relevance to human physiology is not highly satisfied.  
Although cardiovascular disease is considered primarily to affect men170. Since 1984 more 
women than men have died from heart disease. The risk factors are likely to be the same 
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for men and women, but the prevalence and relative risk vary. For example, SLE is more 
common among women than men. Proper study design in a clinical trial is must include 
both genders, as well as subjects of appropriate age and proper statistical design 170. As 
mentioned at the beginning of the introduction, the term vulnerable plaque also high risk 
or unstable plague indicates a higher risk of disruption. However, this concept is based 
primarily on cross-sectional studies or animal models, which have their limitations. Many 
of the techniques of both invasive and non-invasive, used for detection of plaque 
vulnerability171, are not reliable, yet are being utilized more and more.  
Basic research characterized plaque and a possible reason for plaque vulnerability as well 
as identified atherogenic and athero-protective function in atherosclerosis. Atherogenic and 
athero-protective function in atherosclerotic plaque leads to another new approach in 
cardiovascular research, the immunomodulation of the inflammation via active 
immunization or vaccination.  
1.11 Vaccination approach in atherosclerosis  
The vaccine is one of the major advances to eradicate the many infectious diseases. 
Vaccination against chronic inflammatory diseases, including atherosclerosis is being 
considered172. Indeed, research on atherosclerosis has led to the discovery of new aspects 
of adaptive and innate immunity. The idea that specific antigen plays a role in 
atherosclerosis, suggests anti-inflammatory treatment or raising protective antibodies. 
Several animal studies suggest that vaccine against atherosclerosis might be effective173-
177.  
Although Ox-LDL, HSP and Apo-B are generally considered to be potential immunogens 
in this connection, recent focus has been placed on PCSK9 as well178. Most animal studies 
have shown that vaccination with specific immunogens reduced atherosclerosis at early 
stage or attenuated the progression of atherosclerosis, but some controversial results have 
also been obtained. For example, immunization with HSP65 promoted atherosclerosis. 
Vaccine can be administered mucosally, orally or nasally,  and interestingly, mucosal 
administration of HSP65 appeared to be athero-protective while perinatal administration is 
atherogenic179. Immunization with HSP60/65 peptides effective, increases the number of 
T-reg cells, but, surprisingly, detail study is missing since the od of the peptide P210 is not 
recognizesd by mouse MHC II179. The potential risks of long-term immunization are not 
well known at present. In addition, many other challenges in concerning vaccination, 
against atherosclerosis remain, including formulation, route of administration, and the 
safety, stability and duration of immunization as well as appropriate selection of patients 
for testing. 
The potential role of immunogen to atherosclerosis, needs to be addressed first, as does the 
cellular distinction or cellular diversity that plays an important role in inflammation. 
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Vaccination idea can be an avenue against atherosclerosis but, it is still a long journey to 
reach to the destination.  
Much can be learned from patients` samples or data from patients172. Despite all these 
challenges, researchers are optimistic about vaccination or immunomodulation as 
prevention or treatment for atherosclerosis.   
1.12 Treatment of CVD/atherosclerosis: present, future, and challenges  
Many preventive strategies involving lifestyle intervention ,and therapies have been 
designed to reduce the burden of CVD or atherosclerosis180, including hypolipidemic 
drugs, anti-hypertensive therapy, inhibitor of the angiotensin-converting enzyme, blockers 
of the angiotensin-receptor, beta, calcium-channel and anti-platelet/anti-thrombotic 
therapies181. On the basis of clinical and public health concern and in consideration of 
healthy long lives, the burden of cardiovascular disease is the highest than another global 
challenge despite all technological development or advanced treatment182in compare to 
past. Clinical complications and the unclear pathophysiology of this disease can be major 
reasons for the limited success to date.  
Lipid-lowering drugs are more used for prevention of CVD183, 184, some of these drugs 
mainly are of value for symptomatic but not asymptomatic cases184. Statin, the most widely 
used of these drugs for more than 2 decades but has many clinical complications185, and in 
2012 Food and Drug Administration warned against the elevated risk of diabetes  186 and 
other side effects or limitations187. Another limitation is cost in much of the world, statins, 
blood pressure-lowering agents even aspirin are still not affordable188. It has also been 
estimated that the cost for the CVD will increase to 749 billion dollars in 2035.  
Another approved class of lipid-lowering drugs class is inhibitor of PCSK9 (proprotein 
convertase subtilisin/kexin type 9) is now receiving more attention. It was first described 
in 2003189as a potential lipid-lowering therapeutic187, 190  with a different mechanism of 
action190. Monoclonal anti-PCSK9 antibodies are at present in phase III clinical trials190 
and some of the trials already completed and results have already been reported in 2017191. 
Some questions that arise regarding  treatment with monoclonal antibodies185. Concern the 
risk of an immune reaction against the monoclonal antibodies, As well as adverse side 
effects such as target specific effect and cardiotoxicity192. Accordingly, use of aggressive 
statin or other lipid-lowering drugs still remain the treatment of choice for atherosclerosis. 
Although the mechanisms linking of inflammation to atherosclerosis have not yet been 
elucidate in detail, targeting inflammation has produced positive results. For example, a 
recent randomized trial focusing on canakinumab thrombosis outcome study (CANTOS), 
concluded that anti-inflammatory therapy can reduces mortality from CVD193.  At the same 
time, another recent investigation  has raised a question about which anti-inflammatory 
drugs to use194. IL-1 beta is thought to be one of the key regulators of the  plaque formation, 
and CANTOS trial demonstrated treatment with anti-IL-1beta antibody is beneficial193. 
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However,  Gomez and colleagues found that IL-1 beta plays different role at different 
stages of atherosclerosis194, suggesting alternative anti-inflammatory therapy195.  
The CANTOS trail involved participants 10,061 who had developed myocardial infarction 
and inflammation with blood levels of C-reactive proteins >2 µg/ml. Different doses (50, 
150 or 300 mg) of canakinumab were administered and the primary outcomes included 
non-fatal stroke and non-fatal MI.  
Mortality in the canakinumab and placebo groups did not differ significantly but the 
secondary effect was the composite of primary effect as well as urgent vascularization, and 
a significantly higher risk for fatal infection.  
In addition, others anti-inflammatory therapies have been proposed and some are now in 
phase III clinical trial. Methotrexate targets a variety of cytokines and treatment of patients 
with arthritis with this drug lower their risk of CVD. However, application is limited only 
to arthritis patients group.  
Another candidate, colchicine, has multiple targets, including neutrophils, macrophages T-
cells, and mast cells, although, safety with long term use of this medication is still a 
concern. Its mechanism of action mimics in part that of canakinumab. Various studies have 
reported that colchicine reduces CVD but a meta-analysis showed colchicine trial was only 
for short term use to prevent primary or secondary event, whereas an effect on CVD 
requires longer use. The side effects reported, were minimal, but individuals with such 
inside effects were removed at an early stage from the study168.  
Furthermore, micro RNA-based therapy for CVD has been suggested. This is has been 
effective in an animal model but again, in a long time, effect and the efficiency of avoiding 
off-target still a question196. The complex mechanism in atherosclerosis especially 
inflammatory response still much remains to identify197. A deeper understanding of cellular 
involvement in atherosclerosis will be of key importance for development of novel 
drugs/treatment strategies31.  
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2. Aim of the study 
My Ph.D. thesis works focus mainly on immune and/or inflammatory mechanisms 
involved in the initiation and/or progression of atherosclerosis. Specifically, the aim was 
to improve our understanding of the involvement of immunocompetent cells in 
atherosclerosis and the potential therapeutic actions against these pro-inflmmaotry effects. 
In addition, one of our major interests is the risk of atherosclerosis and CVD associated 
with systemic lupus erythematosus. 
To gain insights into the inflammatory mechanisms underlying the formation and/or 
rupture of atherosclerotic plaques and link between autoimmunity and CVD or 
atherosclerosis, our specific aims were to examine the following – 
1. The role of anti-PC and anti-MDA antibodies against atherosclerosis in patients 
with SLE 
2. The mechanisms by which, HSP60 and HSP90 induced inflmmatory mechanisms 
in connection with atherosclerosis 
3. The role of anti-PC antibodies in the polarization of T-reg cells  
4. The potential involvement of MDA in atherosclerosis  
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3.  Methods 
The methods and materials employed are described in detail in the papers on which the 
thesis is based and an overview is provided here. 
3.1 Cell cultures 
In the 18th century when the cell theory was first proposed, it was explained in both plants 
and in the animals at a similar time. Theodor Schwann described the cell as an fundamental 
unit of tissues and the formation of the cells is the main principle of organisms198. Today, 
cell cultures are a widely used and important tool in scientific research, providing disease 
models and production of therapeutic protein.  
 Primary cell cultures hold numerous advantages over cell lines, being more 
physiologically relevant199, 200 but they are more sensitive in comparison to the cell lines 
and require extra care. We used primary cells from healthy individuals and patients who 
had developed atherosclerotic plaques, and suffered from SLE.  
3.2 Cells from healthy donors  
Buffy coats (concentrated blood with more number of cells with the reduced portion of plasma) 
collected from Karolinska University Hospital, Stockholm, Sweden were handled in accordance 
with rules and regulations of the hospital (ref. number- 1-485/2013). Peripheral blood mononuclear 
cells (PBMCs) were then separated on a Ficol-paque density gradient201. In the study, B-cells, T-
cells, DCs and macrophages were used for different study purposes. PBMCs derived monocytes 
were differentiated into DCs or macrophages by treatment with GM-CSF and IL-4 or GM-CSF 
alone respectively. B-cells and T-cells were separated from whole buffy coats or PBMCs with B 
or T-cell enrichment cocktails or positive selection kits. Cells from healthy donors were used in all 
of the studies.  
3.3 Cells from patients with SLE 
Study with SLE patients` cells was approved by the Karolinska University ethical 
committee and all the patients gave their informed consent. Whole blood from SLE patients 
with SLE were collected from Karolinska University Hospital; PBMCs were isolated as 
described above; and T-reg cells investigated in the third study.  
3.4 Cells from atherosclerotic patients 
Ex vivo study with cells from atherosclerotic plaques provides plenty of advantages, 
including the presence of all the important types of immune cells and the structure, can be 
used to explore lesion biology or atherogenesis202.One difficulty working with plaques` 
cells, involves separation of the cells from the fatty streaks. Plaques were collected at 
Södersjukhuset Hospital, Stockholm, Sweden, from patients following endarterectomy of 
carotid or femoral arteries and blood was also collected from the same area undergoing 
surgery. PBMCs were isolated as above. The atherosclerotic plaques were cut into small 
pieces and cells separated after enzymatic treatment. T-cells from total plaque cells were 
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separated by T-cell positive selection kit and utilized in studies II, III and IV to characterize 
mechanisms of immune activation in atherosclerotic plaques.   
 
Fig-3: Human atherosclerotic plaques from a carotid artery 
 
3.5 Trans-well co-culture  
Cell co-culture allows to  examine cell-cell interactions203, which is important for 
atherosclerosis, where different cell types play important roles. We used trans-well co-
cultures to study B-T-cells interactions in connection with the production of antibodies 
against PC and MDA (study I) and DC-T-cell interactions involvement in connection with 
the HSP60-induced DC-mediated activation T-cells. (study II).  
3.6 Gene silencing 
Gene is considered as a basic unit for the biological system. Genetic information is carried 
out through DNA or RNA and finally turn into protein 204. Gene silencing has helped 
unraveled the function of individual genes for more than two decades now. The most 
common tools for gene silencing involves siRNA (small interfering RNA) and shRNA 
(short hairpin RNA), which have both similarities and difference205 but shRNA has certain 
advantages. Silencing with shRNA is more stable than siRNA, lasting for a year, whereas 
with siRNA mediated silencing, the silenced gene can begin to be expressed again after 
48-72 hours. In addition, shRNA mediated silencing is more specific.  
In my first study, shRNA was utilized to silence the CD40 and CD1d genes in B-cells and 
cultured for 6-7 days to study the involvement of these molecules in the production of anti-
PC and anti-MDA IgM antibodies. In the fourth study the TLR4 gene was silenced in T 
cells with shRNA, control shRNA in both cases was used to confirm the specific function 
of the molecules. CD40, CD1d or TLR4 silencing was investigated by RT-qPCR or flow 
cytometry at the gene athe protein level respectively.  
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3.7 Blood serum and plasma  
In biological research, serum and plasma are most commonly used materials206. The serum 
has a higher concentration of metabolites whereas plasma has all the constituents of blood, 
although measuring specific components from both plasma and serum give similar 
results206. We used serum to measure IgM antibodies against PC and MDA. In the case of 
atherosclerotic patient, we separated plasma, and the plasma was used for peptide 
modification by MDA from human serum albumin. Serum from patients with SLE was 
collected from Karolinska University Hospital, Stockholm, Sweden and kept under -80 C˚. 
Blood plasma from atherosclerotic patients were collected at the same time of cell 
separation from blood and was preserved at the same condition as serum.   
3.8 Ultrasound 
Ultrasound (US) is one of the techniques for detection of plaue171. Although limited in 
sensitivity, is inexpensive, high resolution, user-friendly, no radiation, rapid and functional. 
A duplex scanner of 6 MHz was used to detect plaques in the left and right arteries of 
patients with SLE  
3.9 ELISA/ELISPOT 
ELISA developed by Peter and Eva 207 and they publisehd their first paper in 1971 on the 
ELISA measuring IgG antibodies208. Since then, ELISA procedures have been developed 
extensively, and highly sensitive measurement of various proteins, including antibodies 
and cytokines. In our study, we used ELISA for the detection of antibodies and cytokines 
in serum and the medium from cells. Antibodies against PC and MDA were measured with 
protocol developed in house and total IgM antibodies or cytokines with commercially 
available kits. ELISPOT which is similar to ELISA, measures antibody or cytokine 
secreting cells. In the first study, ELISPOT was utilized to detect anti-PC and-MDA 
producing B-cells.   
3.10 Flow cytometry/Fluorescence absorbance cell sorting 
This technique was invented in 1960 by Bonner, Sweet, Hullet, Herzenberg and machines 
for fluorescence absorbance cell sorting (FACS) become commercially available 10 years 
later. This highly sensitive technique can be used to analyze the expression of multiple 
proteins and has a major impact on research in biology, especially in the area of 
immunology209. We used flow cytometry for detection of different cell types and/or their 
activation as well as for the detection of inflammatory pathways, apoptosis, and generation 
of ROS. Flow cytometric data were analyzed with the FlowJo software. 
3.11 RTqPCR 
The polymerase chain reaction (PCR) has a revolutionary impact on the detection and 
quantification of individual gene.  Mullis in 1984, invented PCR and it leads to developing 
real-time PCR210. RT-qPCR was performed using TaqMan or Sybr green reagent as a 
master mix. The level of GAPDH gene expression was used as an internal control and the 
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level of gene expression calculated by ^^CT method. RT-qPCR was used to detect the 
expression level of transcription factors for T-cells (study II, III and IV). In addition, CD40 
and CD1d gene expression in study I, and in study II expression of HSP60 in gene level 
were detected by RT-qPCR.  
3.12 Mass spectrometry 
In the early 20th century, mass spectrometry (MS) was used by physicists to determine an 
atom`s mass, and later on expanded branch to chemistry. During the last two decades this 
tool has exerted a very great impact on biological research, allowing characterization of 
molecules and diagnosis of diseases. The principle was discovered by Josepj James 
Thomson and later Francis Waston designed mass spectrometer. MS widely used in the 
proteomic study. In my studies, we used LC-MS/MS analysis to characterize the peptide 
sequence of anti-PC antibodies (study III) and modification of peptides of human serum 
albumin by MDA in atherosclerotic patients` plasma or in vitro (study IV). Raw data were 
analyzed using DeMix- Q workflow (study III) Mascot v.2.4 database search engine (study 
IV).  
3.13 Microscopy 
The history of invention of the microscope is long but August Kohler`s invention of the 
ultraviolet absorption microscope in 1904 led to the fluorescence microscope. Today`s this 
an extremely important tool in biological research, allowing identification of single specific 
molecules. In study III, fluorescence microscope was used to detect the binding or 
localization of surface proteins, specifically the binding of IgM anti-PC antibodies to CD40 
on dendritic cells.  Microscopic images were analyzed with the Image J software. In 
addition, light microscope was used regularly to monitor the cellular morphology in all my 
projects.  
 3.14 Chromatographic column 
Chromatography was first employed by Mikhail Tsvet in 1903s but a different version was 
developed from 1930-1940. Proteins differ in their size, shape and/or charge, and can be 
separated or purified by chromatographic methods. Column chromatography, which is 
most commonly used for this purpose, has the largest stationary phase 211. Although 
reproducibility is comparatively difficult by column chromatography but a cost-effective 
method.  We used cation-exchange high-trap and gel chromatographic columns for the 
separation and purification of antibody specific for malondialdehyde (study I) or 
phosphorylcholine (study III). Concentration and/or purity of these antibodies was assessed 
by ELISA.  
3.15 BrdU incorporation 
BrdU, an analog of thymidine, is incorporated into specifically into newly synthesized 
DNA during the S phase of cell division and this property has been exploited since the 
1980s to monitor cellular proliferation. This technique is relatively inexpensive and rapid, 
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as well as the working labeling concentration is not toxic. One limitation is that this can be 
incorporated into nuclear DNA during cell repair or cellular regeneration,  but at a rate 
much lower than during cell dividions212. We utilized BrdU incorporation to assess the 
proliferation of dendritic or T-cells in response to HSP60 (study II) or MDA (study IV).  
3.16 Statistical analysis 
In biological research, experimental results have a risk for error, unreliability or 
uncertainty213 but with statistical methods errors can be reduced. A statistical test of 
significance determines the effect of experimental achievement.  A statistical significance 
is not the scientific significance but provides a justification to trust on the data, it mainly 
based on probability calculation213. 
Epidemiological data from a case-control study are analyzed by statistically be comparing 
the disease group (case) to the control group (without disease) to obtain odds ratio. 
In study I, conditional logistic regression was performed to determine the prevalence of 
atherosclerosis in patients with SLE, using the SAS 9.4 software. In the regression model, 
relative risk takes into consideration factors that may influence the relationship between 
prevalence or frequency 214. In the experimental part, of all studies, the two tailed Student 
T-test was applied and p-value <0.05 was considered as statistically significant.  
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4. Results 
Results from all the studies are summarized here. Each result is described with a figure or 
a table in each constituent papers.  
4.1 Study I 
The potential impact of anti-PC and anti-MDA antibodies has been reported previously in 
various cohort studies. Here, the first question in our study, was to identify the relationship 
between these antibodies and risk of CVD in patients with SLE. Logistic regression 
analysis revealed that anti-PC and anti-MDA IgM antibodies together protect against the 
progression of atherosclerosis; levels above the 60th percentile were associated with 
protection, while below the 33rd or 25th percentile the risk was higher. Subsequently, 
laboratory experiments were performed to elucidate the underlying mechanism(s). Uptake 
of apoptotic cells by macrophages was increased in presence of anti-PC or anti-MDA IgM 
antibodies. Moreover, induction of oxidative stress in PBMCs or in monocytes by MDA 
was inhibited by anti-MDA antibodies. The production of these antibodies regulated by T-
cells. Thus, in the absence of T-cells, B-cells did not produce expected levels of either of 
these antibodies but in the presence of T-cells in a mix culture system produced an 
abundant amount. B and T-cells in trans-wells co-culture system did not produce the same 
amount of antibodies as like as mix B and T-cells culture, indicating B-T cells interactions 
are essential for such production.   
Investigation of the molecular mechanism confirmed that production of these antibodies is 
dependent on interactions. To identify the specific molecules involved, CD40, CD1d and 
HLA-II were silenced or inhibited, and silencing or inhibition of CD40 or HLA-II 
molecules, the production of antibodies was attenuated, indicating that adaptive immunity 
plays a role in regulating the production of anti-PC and anti-MDA IgM antibodies.  
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4.2 Study II 
The second study, designed to elucidate the potential role and mechanism of heat shock 
protein(HSP) 60 and HSP90 in immune activation in connection with atherosclerotic 
plaques, and underlying mechanism revealed that both proteins promote the activation and 
maturation of DCs. When HSP60 or HSP90 treated DCs were co-cultured with T-cells 
from the same individual, only the former activated-cells. HSP60 elicited hyperactive DCs 
that produced higher levels of pro-inflammatory cytokines, although a mild elevation of 
the level of the anti-inflammatory cytokine IL-10 was also observed. Similar results were 
found when DCs from the peripheral blood of atherosclerotic patients were exposed to 
HSP60 and subsequently co-cultured with T-cells obtained from the same individual`s 
plaques.  
To identify the type of T-cells aactivation, cytokines levels were determined and the levels 
of the Th1 and Th17-type cytokines INF gamma and IL-17, respectively found to be 
elevated in response to HSP60. This observation was supported by the upregulation of the 
transcription factors T-bet (for Th1) and RORc (for IL-17) by HSP60. Because of the low 
volume of cell culture supernatant, we could only measured INF-gamma in the case 
patients` and the findings were similar. 
 More detail study of T-cell activation revealed that HSP60 is a classical antigen, since 
HLA-II inhibiting antibodies prevented T-cell activation by DCs pre-exposed to HSP60. 
In addition, T-cell activation was inhibited when DCs exposed to HSP60 in presence of 
annexin A5. To investigate the mechanism, we measured HSP60 in the presence or absence 
of annexin A5 and the levels of HSP60 detection was reduced in the presence of annexin 
A5, indicating annexin A5 interacts with HSP60. Furthermore, annexin A5 inhibited Ox-
LDL induced HSP60 production in dendritic cells.  
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4.3 Study III   
In the third study the role of anti-PC IgM antibodies was investigated further. First, we 
were curious whether these antibodies induce T-reg cells derived from healthy donors.  
When PBMCs from healthy donors were cultured in the presence of different 
concentrations of anti-PC IgM or anti-PC flow through (control antibodies) antibodies, the 
proportion of T-reg cells rose in response to anti-PC antibodies, especially with 
concentrations of 2.5 or 5 µg/ml, but 0.2µg, 1µg or 10µg/ml anti-PC antibodies did not 
influence T-reg polarization.  
When we investigated T-reg and Th17 cells in CD4 T-cells from atherosclerotic plaques, 
because of limited number of plaque cells we had to choose a single concentration (5 
µg/ml) of anti-PC antibodies or control antibodies. Again, anti-PC antibodies enhanced the 
number of T-reg cells but not Th17 cells.  
In addition, in the peripheral blood of patients with SLE, the number of T-reg cells was 
lower than in control subjects matched for age and sex. In both groups anti-PC IgM induced 
T-reg cells polarization. In the control group, the number of Th17 was significantly lower 
but neither anti-PC or control antibodies did not alter this amount in either gorup.  
Analysis of transcription factors supported these findings on T-reg and Th17 cells 
polarization. Anti-PC IgM antibodies upregulated the T-reg transcription factor Fox-P3, 
while the transcription factor RORC for Th17 was unaffected.  
Furthermore, anti-PC IgM antibodies did not affect the proinflammatory cytokines TNF-
alpha and IL-17 secretion, although, interestingly, control antibodies induced the secretion 
of both, indicating the pro-inflammatory effects of IgM antibodies those directed to other 
than PC.  
When T-cells alone were stimulated with anti-PC antibodies, the proportion of T-reg cells 
was not influenced. We, therefore, decided to investigate dendritic cells to investigate as 
potential mediators of T-reg cells polarization induced by anti-PC antibodies.  These 
antibodies inhibited activation or maturation of DCs, as reflected in expression of the 
markers CD80, CD86, CD83, CD11C, and HLA-II. These also attenuated the activation of 
NF-kB pathway.  
Subsequent immunocytochemistry analysis revealed that anti-PC IgM antibodies binds to 
DCs in co-localized with CD40. De novo protein sequencing identified the more 
heterogenous variable region of control antibodies (Non anti-PC) in comparison to anti-PC 
antibodies. In comparison to control antibodies, peptides of lamda variable was less in anti-
PC antibodies. Interestingly 7 peptides of HV chain in CDR2 and CDR3 regions were more 
abundant in the anti PC IgM antibodies in comparison to control antibodies.  
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4.4 Study IV 
Here, we investigated activation of immune cells in response to MDA-HSA, with a focus 
on atherosclerosis. We stimulated PBMCs with MDA-HSA and observed activation of T-
cells. Next, we stimulated DCs with MDA-HSA and found activation of DCs. The DCs 
activated by MDA-HSA, secreted pro-inflammatory but not anti-inflammatory cytokines. 
When MDA-HSA-stimulated DCs were co-cultured with T-cells, activation of the latter 
was not pronounced when PBMCs were exposed directly. Next, T-cells stimulated with 
MDA-HSA directly, promoted the activation, in a pattern, as like as PBMCs induced 
activation of T-cells. 
Furthermore, we found that pro-inflammatory Th1 whereas anti-inflmmatory Th2 cells 
were not activated in response to direct stimulation. Anti-MDA antibodies, inhibited the 
activation of T-cells presumably by preventing MDA-HSA from binding to or entering T- 
cells.  
Moreover, MDA-HSA induced generation of ROS in T-cells and inhibition of this 
generation attenuated this activation, indicating mitochondrial ROS involved in MDA-
HSA induced activation of T-cells. In response to stress, induced by MDA-HSA, DCs and 
in particular, T-cells secreted more HSP60.  
Both MDA-HSA itself and T-cells treated with MDA-HSA, stimulated polarization of 
macrophages towards M1 phenotype. MDA-HSA with its danger associated molecular 
pattern, enhanced expression of the pattern recognition receptors TLR2 and TLR4 and, also 
activated the inflammatory pathway p38 MAPK in both T-cells and DCs.  
To understand the immunogenic properties of MDA-HSA, we identified modified peptides 
in human serum albumin conjugated with MDA. There were 30 such peptides modified by 
MDA in vitro. Moreover, such modification of 9 peptides in the plasma of atherosclerosis 
patients were found, two of which were similar to those generated in vitro.  
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5.  Discussion 
The disease etiology of atherosclerosis is complex; it can vary individual to individual 
depending on the inflammatory risk markers. The study suggests the effects depend on the 
age, sex or genetic variation215. Atherosclerosis starts with the damage to the endothelial 
cell, represents difference cellular and molecular responses216.  
My study focused on the immune cells in connection with atherosclerosis. Antibodies are 
produced by B cells, control body’s unpleasant situation in case of infection or in presence 
of unwanted components. The antibodies itself in unregulated condition cause damage to 
bodies own system depending on the level of the antibodies217. First, we studied antibodies 
against phosphorylcholine (PC) and malondialdehyde (MDA). There are, several reports 
on the adverse effect of MDA in both healthy and pathological situations55, 67, 218 , although 
the specific epitopes recognized by anti-MDA antibodies are not exactly identified.  
Here we found that antibodies against both PC and MDA are together strongly associated 
with protection against the formation of atherosclerotic plaques and, of high levels against 
the prevalence of vulnerable plaques. A similar finding in a previous study, was observed 
in our lab that anti-PC together with antibodies against MDA-modified-LDL are protective 
against the development of atherosclerosis219.  In addition, lower levels (especially below 
33rd and 25th percentile) were associated with a higher risk of atherosclerosis progression 
in patients with SLE.  
The risk of CVD is higher in patients with SLE and indeed,  Manzi and co-workers found155  
fifty fold elevation in this risk. Furthermore, the risk of atherosclerosis in patients with SLE 
is higher 220 and plaque rupture and vulnerability are the major causes of CVD6. Vulnerable 
plaques most likely represent by echolucent plaques221, 222 and in SLE, the presence of the 
echolucent plaques are common144.  
Ox-LDL comprised of around three thousand molecules including phospholipids, and 
antibodies against some of their epitopes have been reported.  Antibodies against Apo-B 
or MDA-modified-LDL are found to be as risk factors223-226 whereas protective effects 
were  observed in others 227.  
Such contradictory results might reflect differences in the isotypes of the antibody or the 
nature of Ox-LDL. Generation of Ox-LDL is complex, can be modified in different ways, 
and expression of epitopes can vary and thus produced different types of antibodies. IgM 
antibodies are more likely to be protective.  However, we found antibodies against PC and 
MDA to be protective. In previous study, suggested a potential mechanism for the 
protective role of anti-PC while anti-PC inhibited uptake of Ox-LDL228, further, death 
caused by lysophosphatidylcholine (LPC) was inhibited by anti PC antibodies219. 
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Here, anti-PC and anti-MDA IgM promoted the uptake of apoptotic cells, which is more 
in line with earlier findings, that both increased of uptake of apoptotic cells and reduce 
uptake of Ox-LDL attenuate inflammation. 
Clearance of apoptotic cells is the major issue in patients with SLE, which cause a pro-
inflammatory effect. Dead cells are one of the major characteristics of atherosclerotic 
plaques and defective clearance of apoptotic or dead cells has been implicated156. 
Although, inhibition of Ox-LDL uptake by anti-PC antibodies is beneficial but Ox-LDL 
generate MDA during lipid peroxidation or release more MDA while circulating in the 
blood, and in this context, anti-MDA could be protective. Thus both antibodies could be 
considered as co-operative.  
Comparatively, role of anti-MDA is not much uncovered. In autoimmune diseases, 
including SLE, oxidative stress and the exposers of MDA is increased, and thus increase 
the risk of different diseases including atherosclerosis. Here the finding MDA induced 
oxidative stress inhibition by anti-MDA suggests that anti-MDA balance the oxidative 
stress and thus could play important role in redox balance. 
Anti-PC and anti-MDA antibodies are believed to be T-cell independent, so that one most 
surprising finding is that in the presence of T-cells, the levels of these antibodies increased 
enormously, also confirmed that they are HLA-II mediated, T-cell dependent.  
Soon after we made this obsrvation, at least two other studies provided support for our 
findings 229 230, in one, inhibiting or knocking out CD4 T-cells reduced the levels of these 
antibodies; and the other demonstrated that production of anti-PC antibodies is dependent  
on IL-5.  
Combination antibody therapy of cancer appear promising231 and multi-domain antibodies 
proovide better protection against influenza infection232. Anti-PC and anti-MDA antibodies 
together may offer a novel therapeutic approach against atherosclerosis. Although the level 
of these two antibodies regulated still remain to be elucidated, but our finding shows new 
avenue for future research152.  
However, in addition to Ox-LDL and dead cells, other factors, including HSP, may be 
involved in the inflammation associated with atherosclerotic plaques. In the second study, 
we investigated the potential role of HSP90 and, especially HSP60. In this context, T-cell 
in atherosclerotic plaques has been suggested in several studies233 in particular T-cells 
specific for HSP60 epitopes were identified at an early stage of atherosclerotic plaques234, 
but activation triggering factors are essential to be identified.  
In the context of activation of T-cells, DCs as an antigen presenting cells are important. 
DCs are present in human at early or late stage of plaques also it has been found more in 
vulnerable plaques107, 108.  
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Co-localization of DCs and T-cells in plaques indicating the immune reaction235. In 
addition to human, DCs are also present in mouse at all stages of atherosclerotic plaques, 
participating in plaques pathogenesis236, 237. Although in mice, DCs induce 
thrombogenesis, activation of  T-cells and pro-inflammatory activity was reported 238, the  
HSP60 mediated underlying immune mechanism especially in connection with  
atherosclerosis was not much clear.  
A role for HSP, in the immune reactions associated with atherosclerosis has been indicated 
in several findings. For example, HSP60 stimulated DCs prmote Th1 phenotype239, 240,  
here, our study, shows the extension of those findings, especially in the context of 
atherosclerosis. The controversial role of IL-17 in connection with atherosclerosis, clarifies 
in some extent according to previous findings121. In presence of higher levels of IL-10, IL-
17 may have protective roles by reducing INF-gamma whereas in the presence of higher 
level of INF-gamma, IL-17 elevated risk for progression of atherosclerosis and vulnerable 
plaques. In this context, HSP60 induced IL-17 and also could be a pro-atherogenic under 
circumstances, including with the higher levels of INF-gamma.  
Indeed, antibodies against HSP65 are associated with atherosclerosis and hypertension. 
Our present demonstration indicates that the production of HSP60 antibodies is dependent 
on T-cells, in this context, could also indicate a link to autoimmunity.  
Simultaneously, another study 241 reported autoimmunity to HSP60 in obese mice, with an 
association of the proliferation of T-cells and production of IgG1 and IgG2 antibodies 
against HSP60.  
However, HSP60 might participate in pro-inflammatory activity and thus in atherosclerosis 
in several ways. Ox-LDL promotes pro-inflammatory activity by inducing HSP, and the 
immune action of Ox-LDL is dependent on HSP60/9081, although dependence on HLA-II 
was not shown.  
We found that both HSP60 and HSP90 activate DCs but HSP90 stimulated DCs cannot 
activate T-cells. Possibly, peptides of HSP90 are not immunogenic or lose their 
immunogenicity after endocytosis by DCs. Even if HSP90 acts via another mechanism, 
both HSP60 and HSP90 are circulating in plasma, and have been proposed to be risk 
markers of CVD. 
 Annexin A5 is a plasma protein also has an anti-thrombotic effect. Previously our group 
identified anti-atherosclerosis properties of annexin A5 in both in vivo and ex vivo.  Ex-
vivo, pro-inflammatory activation of T-cells by Ox-LDL was inhibited by annexin A5, and 
T-reg cells polarized in response to protein81, 242. In the present study, this might reflect the 
complex structure of Ox-LDL, so it could explain from a different corner. Ox-LDL induced 
immune activation could involve HSP60 as one mechanism. Annexin A5 was anti-
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inflammatory in both cases but no polarization of T-reg cells was observed in the present 
study. 
Importantly, both studies confirmed that annexin A5 does not cause polarization of T-reg 
cells under healthy conditions. Here, annexin A5 showed indication of interacting with 
HSP60, and if so, might suppress HSP60-induced immune activation by competing for its 
receptors, including those on DCs. Anti-HSP60 antibodies as an immune complex are pro-
inflammatory, in this context it also possible that annexin A5 inhibits binding of this 
antibodies to HSP60 and thus the pro-inflammatory effect.   
In the third study, anti-PC IgM induced polarization of T-reg cells, so it will be interesting 
to study HSP60 induced immune activation in presence of anti-PC IgM antibodies.  
Antibodies against PC could promote the polarization of T-reg cells, but not IL-17 T-cells 
in individuals with SLE and, sex and population-based control group. This finding shows 
significance in the fields of autoimmune disease as well atherosclerosis. T-reg cell has 
more importance in autoimmune diseases, the immunomodulatory function of T-reg cell 
control the immune activation but in an impaired situation when T-reg cell`s function is 
interrupted can lead to autoimmune disease. Induction of T-reg cells  in different diseases 
including CVD was suggested as therapeutic option243. The proportion of T-reg cells in the 
SLE group found to be less than control group244 also was confirmed by other study245. It 
is still not identified the reason for the reduced proportion of T-reg cells in SLE but may 
be potentially the affected circulatory environment in SLE. The proportion of T-reg in 
similar line in our experiment, the proportion of T-reg cells was less in patients with SLE 
was restored to normal by anti-PC IgM antibodies.  
 We also found that polarization of IL-17 and T-reg cells is the opposite in healthy 
individuals and those with SLE. As shown in first study, antibodies against PC and MDA 
protect against atherosclerosis and this may be the explanation with polarization of T-reg 
cells, suggesting multiple activities of anti-PC antibodies.  
In addition, production of these antibodies was T-cell- dependent, showing the involvement 
of adaptive immunity, whereas the third project demonstrated that anti-PC antibodies are 
involved in controlling-adaptive immunity, perhaps creating a feedback loop.  
Cytokines of the Th1246 and Th17 247, 248types are abundant in both advanced and vulnerable 
plaques. The regulation of Th17 and T-reg cells, is in general, negatively correlated, and 
in this context T-reg with a lower number could promote atherosclerosis.  
In this manner, these later findings may be relevant to the first study, wherein patients with 
SLE, circulating levels of anti-PC antibodies and prevalence of atherosclerosis were 
negatively correlated.  In combination with the second study, this also indicates an 
important role for DCs in connection with atherosclerosis.  
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Induction of T-reg cells polarization by anti-PC antibodies appeared to be dependent on 
other cells types, at least DCs. These antibodies on T-cells alone did not promote such 
polarization whereas PBMCs stimulated with these antibodies did. Anti-PC antibodies 
affected the maturation and activation of DCs, reduced basal inflammatory condition, 
which may explain these findings. Although CD40 on DCs,  the potential binding site for 
anti-PC antibodies, more investigation remains to establish and identify additional 
potential site.  
Since, antibodies other than those against PC do not exhibit similar properties, using de 
novo protein sequencing, we characterized their peptides. The peptides of variable region 
of control antibodies was more heterogenous, indicating anti-PC structure is lees complex 
and perhaps more specific.  
Although, we did not characterize sequence homology between anti-PC and anti-MDA 
antibodies, the anti-MDA antibodies probably act in a different manner, at least with 
respect to T-reg polarization, even though they were also a protective in the first study.  
In our fourth study, anti-MDA antibodies inhibited pro-inflammatory activation of T-cells 
by MDA-HSA. Effects of MDA on different cell types in healthy and atherosclerotic 
individuals was investigated. The adverse effects of Ox-LDL are still not clear,  and a 
concentration-dependent beneficial role has also been reported249. Its effects, could also 
depend on the nature of Ox-LDL, as well as the products of lipid peroxidation e.g., MDA.  
Ox-LDL induced activation of T-cells from plaques confirmed in several studies81, 250. In 
addition to peripheral blood T-cells, here, we studied also T-cells obtained from plaques, 
induced by MDA-HSA.  Our results suggest that T-cells in peripheral blood or in plaques 
can be activated by MDA more strongly without DCs. This activation leads to pro-
inflammatory differentiation into mainly Th1 type T cells, without cells proliferation upon 
direct activation, in line with the previous finding of Ox-LDL 81. Activation of pro-
inflammatory T-cells and DCs activation are considered to be a major cause of plaque 
rupture, as well as common phenomenon in vulnerable plaques108, 109. Accordingly, our 
finding also reveals the factor responsible for plaque rupture and thus the progression of 
CVD.  
The MDA, a danger associated molecular pattern, its presence in atherosclerotic plaques 
has long been known and it is considered to be a marker of stress in connection with various 
diseases, including atherosclerosis and SLE.  
Immunization with MDA-modified-LDL in mice has been shown to be athero-protective, 
MDA can form adducts with different proteins, including serum albumin produced in the 
liver but most abundant protein in blood plasma251. Here, we found that MDA modified 
peptides derived from HSA both in vitro and in the plasma of atherosclerotic patients, 
demonstrating immunogenicity. Interestingly, 2 of these peptides modified were similar in 
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both cases. The possibilities that MDA also modifies HSA and causes immune activation 
in healthy individuals as well cannot be excluded.  
Both antibodies anti-PC and anti-MDA antibodies are protective and their production 
depend on T-cells, since among 2 epitopes of Ox-LDL, MDA is pro-inflammatory, we 
focused on these and especially T-cells activation. Moreover, Ox-LDL induces immune 
activation through HSP60, we, showed that HSP60 is a classical T-cell antigen. 
MDA induced HSP60 more potently in T-cells than DCs derived from both blood and 
plaques. May be therefore, MDA-HSA-induced DCs-mediated activation of T-cell does 
not follow the same mechanism as Ox-LDL did, but MDA-HSA- induced secreted HSP60 
by T-cells could be processed by DCs and thus can be recycled to T-cells as antigen. Since 
according to the second study, HSP60 induces pro-inflammatory T-cells, MDA could 
contribute to plaque inflammation in this manner.  
In addition, HSP60 is induced by toxic or stressful conditions that elevate the levels of 
ROS, here we found that activation of T-cells by MDA-HSA is partly dependent on ROS, 
especially those generated in mitochondria, a novel insight, and thus may play role in cell 
death in plaques.  
TLR acts as an agonist for many microbial or non-microbial epitopes, but in our study 
MDA-HSA was not recognized by at least TLR2 or TLR4 in the T-cells. Possibly MDA-
HSA bind directly to membrane proteins on T-cells and/or enters T-cells though diffusion. 
In the case of DCs and macrophages, MDA-HSA can be recognized by CD36 on the cells 
surface but highly important question of recognition by T-cells remains to be identified.  
Another important finding was the effect of MDA on macrophages. In connection with 
atherosclerosis, macrophages play key role at all stages. In general, M1 macrophages, 
considered to be more pro inflammatory, are associated with type Th1 cellular responses 
and induce proinflammatory cytokines; whereas M2 macrophages are considered to be 
involved in the repair process associated with Th2 cells.   
TLR2 and TLR4 has been implicated in chronic inflammatory conditions, and inhibition 
of them has been proposed as a therapeutic approach to cardiovascular disease. Although, 
activation of T-cells by MDA-HSA was not dependent on them, induced the expression of 
both TLR2 and TLR4 in both DCs and T-cells. In this manner, MDA-HSA might accelerate 
inflammation in atherosclerosis plaques and promote CVD through innate immune 
reaction.  
Again, it has been believed that all autoantibodies in autoimmune diseases, including SLE, 
are pathogenic factors but some antibodies appeared to be protective in connection with  
atherosclerosis152 and it is important to clarify which is which, among other reasons, 
therapeutic purposes.  Our study, an unexpected finding of T-cell involvement in the 
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production of autoantibodies, suggests a role of adaptive immunity in the production of 
antibodies against product of lipid peroxidation. The different levels of such antibodies in 
different individuals, might reflect different numbers of CD4 T-cells and/or levels of pro-
inflammatory cytokines. In addition, immunosuppressive role of T-reg is important 
function to control immune reaction against self-antigens. 
The observation in our second study that HSP60 is a classical T-cell antigen, interesting in 
light of a report on autoimmune response against this protein 241. In this regards, anti-PC 
IgM antibodies could control the adaptive response against HSP60. In our third study, anti-
PC antibodies, interrupted both DCs maturation and the NF-kB inflammatory pathway. In 
this manner, HSP60 and HSP90 induced activation and maturation of DCs may be 
potentially limit by the anti-PC antibodies. Influence of anti-PC antibodies on HSP60 
stimulated activation of T-cells remains to be identified.  
Antibodies to MDA induced phagocytic activity, and inhibited MDA induced stress 
without influencing polarization of T-reg cells. 
Our other study on a cohort of 60-year-olds revealed that anti-MDA IgM protects against 
atherosclerosis and lower the risk of CVD143. This finding may reflect increased clearance 
of apoptotic cells in the first study. Apoptosis, mechanism still not fully uncovered but in 
the elderly the rate of apoptosis is relatively higher, reducing myocytes by 30% 252. Perhaps 
due to, at least in part to a higher levels of oxidative stress.  
However, reports 253 254 documented a correlation between the elevated levels of MDA IgG 
antibodies and disease activity in connection with arthritis or SLE, but no explanation 
provided. Possibly, in stress situation with the higher levels of MDA, antibodies increased, 
but it is important to identify the exact functional role and regulation of anti-MDA IgG 
antibodies in those condition. However, in our study MDA appeared to be more important 
component to induce pro-inflammatory immune cells activation.  
Figure 4 based on our findings together, illustrates possible pro-inflammatory or anti-
inflammatory mechanisms that may be involved in atherosclerosis prevalence or 
atherosclerosis.  
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Fig-4: Inflmmaotry effect in the context of atherosclerosis in individuals with or without SLE and low (A) or 
high (B) levels of anti PC and anti MDA IgM antibodies, or with (A) or without (B) annexin A5.  
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6.  Conclusion and future perspective  
According to the latest update in 2018255, global mortality from CVD was 17.9 million in 
2015,188 and is expected to rise 23.6 million by 2030,  with associated medical costs, 
estimated to be 749 billion dollars in 2035. Thus CVD accounted for 31% of all deaths and 
45% from those noninfectious diseases.  
Information gathering on diseases epidemiology, clinical, scientific basic research, and 
some other related data pointing mostly on the complexity of the mechanism of the disease, 
and in this context, cellular inflammation has receiving more attention.  
Here, in my study, we show that anti-PC and anti-MDA IgM antibodies protects against 
CVD, and act against plaque inflammation. Protective role of these antibodies in 
autoimmune diseases, in connection with atherosclerosis, is necessary to investigate in 
larger cohort. Effect of pro-inflammatory cytokines in the regulation of anti-PC and anti-
MDA antibodies may be interesting for investigation.  
Furthermore, we identified HSP especially HSP60 and MDA as two important pro-
inflammatory components in connection with atherosclerosis, and annexin A5 and anti-
MDA antibodies and/or ROS are potential inhibitors respectively. 
HSP60-annexin A5 interaction, further study with different method is important, which 
might will clarify whether they interact each other or compete for a binding site. In our 
study, the impact of HSP90 in connection with atherosclerosis, did not provide detail 
information, further investigation required. 
Identifying MDA-modified immunogenic effect of certain other proteins such as Apo-B or 
collagen will be interesting in connection with atherosclerosis and/or in autoimmune 
diseases. MDA is pro-inflammatory in different ways; direct effect of activation of T-cells 
might be controlled by anti-MDA antibodies. Remaining concern on MDA induced 
activation of DCs and thus T-cells, possibly, anti-PC might be useful to suppress the MDA 
induced DCs activation primarily. Potential role of other immune cell types including 
neutrophil in connection with atherosclerosis may will reveal further information, since, 
Ox-LDL induced neutrophil extracellular trap formation already reported, in this context, 
may be MDA have possible effect on them.  
Anti-PC and anti-MDA antibodies are protective in different ways and in this context, 
immunization against PC and/or PC and MDA might help to prevent CVD, although all 
other isotypes of these antibodies remains to be studied more.   
Although several studies suggest anti-inflammatory properties of PC epitopes, detailed 
investigation of the role of PC in CVD is highly motivated. Investigation of possible 
correlation between annexin A5 and autoantibodies could provide valuable information.  
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However, others potential therapeutics such as inhibitor of IL1-beta or PCSK9 may still be 
considered in certain situation, e.g., depending on the disease context. These all potentials 
soldiers, including anti-PC and anti-MDA antibodies, ROS inhibitor and annexin A5 might 
fight unfavorable immune responses together or in appropriate manner.  
However, it is general but again, proper study plan, inclusion of all-important factors in the 
study plan should be followed, reproducibility especially reliability is much important. 
Reliable and strong research should be our commitment for a constructive cardiovascular 
research. 
My findings point a picture of immunologic cellular inflammation and potential therapeutic 
possibilities in connection with atherosclerosis. Further investigation studies including in 
vivo are necessary to confirm some of these findings.  
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